NR576-NR 576 Advanced Pharmacology
exam guide with 150 Practice Questions
NP-Level Prescribing Concepts Straight Answers
This is a document that covers question set covering standard advanced pharmacology/prescribing course subject areas
(pharmacokinetics/pharmacodynamics, cardiovascular, antimicrobial, respiratory, endocrine, psychiatric/CNS, pain
management and controlled substances, GI, renal, dermatologic/immune, and
pediatric/geriatric/pregnancy/anticoagulation/prescribing-safety considerations). Correct answers are bolded and
highlighted.
1. Pharmacokinetics & Pharmacodynamics
1. First-pass metabolism primarily reduces the bioavailability of orally administered drugs by metabolizing
them in the:
A) Kidneys before reaching circulation
B) Liver before reaching systemic circulation
C) Lungs before absorption occurs
D) Stomach before absorption begins
Answer: B) Liver before reaching systemic circulation
2. A drug with a high volume of distribution suggests that the drug:
A) Remains primarily within the vascular compartment
B) Distributes extensively into tissues outside the vascular compartment
C) Is not absorbed systemically
D) Is eliminated primarily unchanged in urine
Answer: B) Distributes extensively into tissues outside the vascular compartment
3. Drugs that are highly protein-bound can lead to clinically significant interactions when co-administered
with another highly protein-bound drug because:
A) Protein binding has no clinical relevance to drug interactions
B) Competition for binding sites can increase the free (active) concentration of one or both drugs
C) Protein binding always increases drug metabolism
D) Protein-bound drugs cannot be displaced by other medications
Answer: B) Competition for binding sites can increase the free (active) concentration of one or both drugs
4. Zero-order kinetics differs from first-order kinetics in that:
A) A constant amount of drug is eliminated per unit time regardless of concentration, rather than a
constant percentage
B) A constant percentage of drug is eliminated regardless of concentration
C) Elimination rate is always proportional to dose in zero-order kinetics
D) No difference exists between the two kinetic models
Answer: A) A constant amount of drug is eliminated per unit time regardless of concentration, rather than
a constant percentage
5. The cytochrome P450 (CYP450) enzyme system is most directly involved in which pharmacokinetic process?
A) Absorption
, B) Hepatic metabolism of many drugs
C) Renal excretion exclusively
D) Distribution into adipose tissue only
Answer: B) Hepatic metabolism of many drugs
6. A CYP450 enzyme inducer (e.g., rifampin) co-administered with a drug metabolized by that enzyme will
most likely:
A) Increase the serum concentration of the affected drug
B) Decrease the serum concentration and effect of the affected drug by increasing its metabolism
C) Have no effect on the affected drug's metabolism
D) Only affect drugs given intravenously
Answer: B) Decrease the serum concentration and effect of the affected drug by increasing its metabolism
7. A CYP450 enzyme inhibitor (e.g., certain azole antifungals) co-administered with a drug metabolized by that
enzyme will most likely:
A) Decrease the serum concentration of the affected drug
B) Increase the serum concentration and risk of toxicity of the affected drug
C) Have no clinically relevant effect
D) Only affect topical formulations
Answer: B) Increase the serum concentration and risk of toxicity of the affected drug
8. A drug's half-life is best defined as:
A) The time required for the drug to reach peak concentration
B) The time required for the plasma concentration of the drug to decrease by half
C) The total duration of drug action
D) The time required for complete elimination of the drug
Answer: B) The time required for the plasma concentration of the drug to decrease by half
9. Renal impairment most significantly affects the dosing of medications that are primarily eliminated via
which route?
A) Hepatic metabolism exclusively, with minimal renal excretion
B) Renal excretion, requiring dose adjustment in clients with decreased renal function
C) Pulmonary excretion
D) Biliary excretion exclusively
Answer: B) Renal excretion, requiring dose adjustment in clients with decreased renal function
10. Therapeutic drug monitoring (e.g., for medications with a narrow therapeutic index) is important because:
A) These medications have a wide margin of safety, requiring no monitoring
B) Small changes in serum concentration can result in either subtherapeutic effect or toxicity, requiring
careful monitoring
C) Monitoring is only relevant for topical medications
D) These medications are never associated with adverse effects
Answer: B) Small changes in serum concentration can result in either subtherapeutic effect or toxicity,
requiring careful monitoring
,2. Cardiovascular Pharmacology
11. ACE inhibitors are generally considered first-line therapy for hypertension in clients with which comorbid
condition, given renal protective effects?
A) Asthma
B) Diabetes with proteinuria/chronic kidney disease
C) Hyperkalemia as the sole condition, unrelated to renal protection
D) Pregnancy
Answer: B) Diabetes with proteinuria/chronic kidney disease
12. A key counseling point for a client newly started on an ACE inhibitor is to monitor for which class-
associated adverse effect?
A) Hypoglycemia
B) A persistent dry cough and the risk of angioedema
C) Weight gain as the primary concern
D) Photosensitivity
Answer: B) A persistent dry cough and the risk of angioedema
13. Beta-blockers should be used cautiously in clients with which comorbid condition due to risk of
bronchospasm?
A) Hypertension alone
B) Asthma/reactive airway disease (particularly non-selective beta-blockers)
C) Type 2 diabetes exclusively
D) Osteoporosis
Answer: B) Asthma/reactive airway disease (particularly non-selective beta-blockers)
14. Thiazide diuretics are commonly associated with which electrolyte disturbance requiring monitoring?
A) Hyperkalemia
B) Hypokalemia and hyponatremia
C) Hypercalcemia as the primary concern with no other electrolyte effects
D) Hypernatremia exclusively
Answer: B) Hypokalemia and hyponatremia
15. Statins carry a prescribing consideration to monitor for which potential adverse effect, particularly with
drug interactions that increase statin levels?
A) Hypoglycemia
B) Myopathy/rhabdomyolysis, especially with certain drug interactions (e.g., some macrolides, azole
antifungals)
C) Hypertension as the primary concern
D) Hyperthyroidism
Answer: B) Myopathy/rhabdomyolysis, especially with certain drug interactions (e.g., some macrolides,
azole antifungals)
16. Warfarin's anticoagulant effect can be significantly altered by dietary vitamin K intake because:
A) Vitamin K has no relationship to warfarin's mechanism
B) Warfarin works by inhibiting vitamin K-dependent clotting factor synthesis, so fluctuating vitamin K
intake can alter INR stability
, C) Vitamin K increases warfarin absorption exclusively
D) Vitamin K is used to reverse all anticoagulants equally
Answer: B) Warfarin works by inhibiting vitamin K-dependent clotting factor synthesis, so fluctuating
vitamin K intake can alter INR stability
17. A prescriber considering a direct oral anticoagulant (DOAC) instead of warfarin for a client with atrial
fibrillation should be aware that DOACs generally:
A) Require the same frequency of INR monitoring as warfarin
B) Do not require routine INR monitoring but still carry bleeding risk and specific renal dosing
considerations
C) Have no bleeding risk at all
D) Are always preferred regardless of renal function
Answer: B) Do not require routine INR monitoring but still carry bleeding risk and specific renal dosing
considerations
18. Digoxin's narrow therapeutic index requires monitoring for toxicity, particularly in clients with which
electrolyte imbalance that increases digoxin sensitivity?
A) Hyperkalemia
B) Hypokalemia, which increases the risk of digoxin toxicity
C) Hypercalcemia exclusively
D) Hypernatremia
Answer: B) Hypokalemia, which increases the risk of digoxin toxicity
19. Amiodarone, used for various arrhythmias, requires long-term monitoring of which organ systems due to
potential toxicity?
A) Only renal function
B) Thyroid, pulmonary, hepatic, and ophthalmologic monitoring given its broad toxicity profile
C) Only musculoskeletal system
D) No monitoring is needed with long-term use
Answer: B) Thyroid, pulmonary, hepatic, and ophthalmologic monitoring given its broad toxicity profile
20. A prescriber initiating an ACE inhibitor should obtain baseline and follow-up monitoring of which lab
values?
A) Only fasting glucose
B) Serum creatinine/renal function and potassium level
C) Only liver function tests
D) Only complete blood count
Answer: B) Serum creatinine/renal function and potassium level
exam guide with 150 Practice Questions
NP-Level Prescribing Concepts Straight Answers
This is a document that covers question set covering standard advanced pharmacology/prescribing course subject areas
(pharmacokinetics/pharmacodynamics, cardiovascular, antimicrobial, respiratory, endocrine, psychiatric/CNS, pain
management and controlled substances, GI, renal, dermatologic/immune, and
pediatric/geriatric/pregnancy/anticoagulation/prescribing-safety considerations). Correct answers are bolded and
highlighted.
1. Pharmacokinetics & Pharmacodynamics
1. First-pass metabolism primarily reduces the bioavailability of orally administered drugs by metabolizing
them in the:
A) Kidneys before reaching circulation
B) Liver before reaching systemic circulation
C) Lungs before absorption occurs
D) Stomach before absorption begins
Answer: B) Liver before reaching systemic circulation
2. A drug with a high volume of distribution suggests that the drug:
A) Remains primarily within the vascular compartment
B) Distributes extensively into tissues outside the vascular compartment
C) Is not absorbed systemically
D) Is eliminated primarily unchanged in urine
Answer: B) Distributes extensively into tissues outside the vascular compartment
3. Drugs that are highly protein-bound can lead to clinically significant interactions when co-administered
with another highly protein-bound drug because:
A) Protein binding has no clinical relevance to drug interactions
B) Competition for binding sites can increase the free (active) concentration of one or both drugs
C) Protein binding always increases drug metabolism
D) Protein-bound drugs cannot be displaced by other medications
Answer: B) Competition for binding sites can increase the free (active) concentration of one or both drugs
4. Zero-order kinetics differs from first-order kinetics in that:
A) A constant amount of drug is eliminated per unit time regardless of concentration, rather than a
constant percentage
B) A constant percentage of drug is eliminated regardless of concentration
C) Elimination rate is always proportional to dose in zero-order kinetics
D) No difference exists between the two kinetic models
Answer: A) A constant amount of drug is eliminated per unit time regardless of concentration, rather than
a constant percentage
5. The cytochrome P450 (CYP450) enzyme system is most directly involved in which pharmacokinetic process?
A) Absorption
, B) Hepatic metabolism of many drugs
C) Renal excretion exclusively
D) Distribution into adipose tissue only
Answer: B) Hepatic metabolism of many drugs
6. A CYP450 enzyme inducer (e.g., rifampin) co-administered with a drug metabolized by that enzyme will
most likely:
A) Increase the serum concentration of the affected drug
B) Decrease the serum concentration and effect of the affected drug by increasing its metabolism
C) Have no effect on the affected drug's metabolism
D) Only affect drugs given intravenously
Answer: B) Decrease the serum concentration and effect of the affected drug by increasing its metabolism
7. A CYP450 enzyme inhibitor (e.g., certain azole antifungals) co-administered with a drug metabolized by that
enzyme will most likely:
A) Decrease the serum concentration of the affected drug
B) Increase the serum concentration and risk of toxicity of the affected drug
C) Have no clinically relevant effect
D) Only affect topical formulations
Answer: B) Increase the serum concentration and risk of toxicity of the affected drug
8. A drug's half-life is best defined as:
A) The time required for the drug to reach peak concentration
B) The time required for the plasma concentration of the drug to decrease by half
C) The total duration of drug action
D) The time required for complete elimination of the drug
Answer: B) The time required for the plasma concentration of the drug to decrease by half
9. Renal impairment most significantly affects the dosing of medications that are primarily eliminated via
which route?
A) Hepatic metabolism exclusively, with minimal renal excretion
B) Renal excretion, requiring dose adjustment in clients with decreased renal function
C) Pulmonary excretion
D) Biliary excretion exclusively
Answer: B) Renal excretion, requiring dose adjustment in clients with decreased renal function
10. Therapeutic drug monitoring (e.g., for medications with a narrow therapeutic index) is important because:
A) These medications have a wide margin of safety, requiring no monitoring
B) Small changes in serum concentration can result in either subtherapeutic effect or toxicity, requiring
careful monitoring
C) Monitoring is only relevant for topical medications
D) These medications are never associated with adverse effects
Answer: B) Small changes in serum concentration can result in either subtherapeutic effect or toxicity,
requiring careful monitoring
,2. Cardiovascular Pharmacology
11. ACE inhibitors are generally considered first-line therapy for hypertension in clients with which comorbid
condition, given renal protective effects?
A) Asthma
B) Diabetes with proteinuria/chronic kidney disease
C) Hyperkalemia as the sole condition, unrelated to renal protection
D) Pregnancy
Answer: B) Diabetes with proteinuria/chronic kidney disease
12. A key counseling point for a client newly started on an ACE inhibitor is to monitor for which class-
associated adverse effect?
A) Hypoglycemia
B) A persistent dry cough and the risk of angioedema
C) Weight gain as the primary concern
D) Photosensitivity
Answer: B) A persistent dry cough and the risk of angioedema
13. Beta-blockers should be used cautiously in clients with which comorbid condition due to risk of
bronchospasm?
A) Hypertension alone
B) Asthma/reactive airway disease (particularly non-selective beta-blockers)
C) Type 2 diabetes exclusively
D) Osteoporosis
Answer: B) Asthma/reactive airway disease (particularly non-selective beta-blockers)
14. Thiazide diuretics are commonly associated with which electrolyte disturbance requiring monitoring?
A) Hyperkalemia
B) Hypokalemia and hyponatremia
C) Hypercalcemia as the primary concern with no other electrolyte effects
D) Hypernatremia exclusively
Answer: B) Hypokalemia and hyponatremia
15. Statins carry a prescribing consideration to monitor for which potential adverse effect, particularly with
drug interactions that increase statin levels?
A) Hypoglycemia
B) Myopathy/rhabdomyolysis, especially with certain drug interactions (e.g., some macrolides, azole
antifungals)
C) Hypertension as the primary concern
D) Hyperthyroidism
Answer: B) Myopathy/rhabdomyolysis, especially with certain drug interactions (e.g., some macrolides,
azole antifungals)
16. Warfarin's anticoagulant effect can be significantly altered by dietary vitamin K intake because:
A) Vitamin K has no relationship to warfarin's mechanism
B) Warfarin works by inhibiting vitamin K-dependent clotting factor synthesis, so fluctuating vitamin K
intake can alter INR stability
, C) Vitamin K increases warfarin absorption exclusively
D) Vitamin K is used to reverse all anticoagulants equally
Answer: B) Warfarin works by inhibiting vitamin K-dependent clotting factor synthesis, so fluctuating
vitamin K intake can alter INR stability
17. A prescriber considering a direct oral anticoagulant (DOAC) instead of warfarin for a client with atrial
fibrillation should be aware that DOACs generally:
A) Require the same frequency of INR monitoring as warfarin
B) Do not require routine INR monitoring but still carry bleeding risk and specific renal dosing
considerations
C) Have no bleeding risk at all
D) Are always preferred regardless of renal function
Answer: B) Do not require routine INR monitoring but still carry bleeding risk and specific renal dosing
considerations
18. Digoxin's narrow therapeutic index requires monitoring for toxicity, particularly in clients with which
electrolyte imbalance that increases digoxin sensitivity?
A) Hyperkalemia
B) Hypokalemia, which increases the risk of digoxin toxicity
C) Hypercalcemia exclusively
D) Hypernatremia
Answer: B) Hypokalemia, which increases the risk of digoxin toxicity
19. Amiodarone, used for various arrhythmias, requires long-term monitoring of which organ systems due to
potential toxicity?
A) Only renal function
B) Thyroid, pulmonary, hepatic, and ophthalmologic monitoring given its broad toxicity profile
C) Only musculoskeletal system
D) No monitoring is needed with long-term use
Answer: B) Thyroid, pulmonary, hepatic, and ophthalmologic monitoring given its broad toxicity profile
20. A prescriber initiating an ACE inhibitor should obtain baseline and follow-up monitoring of which lab
values?
A) Only fasting glucose
B) Serum creatinine/renal function and potassium level
C) Only liver function tests
D) Only complete blood count
Answer: B) Serum creatinine/renal function and potassium level
